Boston Advisors’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q1
Sell
-10,061
Closed -$339K 683
2014
Q4
$339K Hold
10,061
0.01% 437
2014
Q3
$352K Hold
10,061
0.02% 417
2014
Q2
$331K Sell
10,061
-300
-3% -$10.3K 0.01% 454
2014
Q1
$382K Sell
10,361
-1,992
-16% -$73.1K 0.02% 394
2013
Q4
$474K Sell
12,353
-1,057
-8% -$33.4K 0.02% 347
2013
Q3
$367K Sell
13,410
-1,832
-12% -$43.4K 0.02% 363
2013
Q2
$320K Buy
+15,242
New +$298K 0.02% 386

Other funds holding WX

Boston Advisors's WX Position: Q1 2015 in Review

Boston Advisors sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q1 2015, closing a stake of 10,061 shares — an estimated $339K sold.

Boston Advisors first reported a position in WX in Q2 2013 and held it in 7 quarters. The position peaked at $474K in Q4 2013. 147 funds tracked by Wall St. Rank hold WX as of Q1 2015.

  • Boston Advisors reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q1 2015 after selling out during the quarter.
  • Boston Advisors sold 10,061 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q1 2015, an estimated $339K.
  • Boston Advisors first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 7 quarters.
  • Boston Advisors's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $474K in Q4 2013.
  • 147 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q1 2015.

Based on Boston Advisors's 13F filing for Q1 2015, filed 21 Apr 2015.